Simple model for the study of Pseudomonas aeruginosa infections in leukopenic mice

A simple, reproducible model of fatal Pseudomonas aeruginosa sepsis in mice during immunosuppression was developed. Mice were rendered leukopenic (less than or equal to 800 leukocytes per mm3 of blood) for a period of 5 days by multiple injections of cyclophosphamide. Mice were challenged at the onset of leukopenia by instilling the bacteria onto a 0.5-mm incision made into the back. The mean lethal dose (LD50) for P. aeruginosa PA220 and M-2 was less than 20 bacteria. The mean time to death for these strains ranged from 46 to 59 h. Leukopenic mice were comparatively resistant when challenged with Klebsiella pneumoniae (LD50 = 1.5 x 10(6)) or Staphylococcus aureus (LD50 greater than 10(6)). Infection with P. aeruginosa was characterized by rapid bacterial multiplication in the skin at the site of infection, producing ecthyma gangrenosum. Bacteremia and colonization of the liver were pronounced 21 h postinfection. This model should prove to be a useful tool for studying the pathogenesis of P. aeruginosa infections under immunosuppressed conditions.

[1]  I. A. Holder,et al.  Flagellar preparations from Pseudomonas aeruginosa: animal protection studies , 1982, Infection and immunity.

[2]  E. Ziegler,et al.  Pseudomonas aeruginosa vasculitis and bacteremia following conjunctivitis: a simple model of fatal pseudomonas infection in neutropenia. , 1979, The Journal of infectious diseases.

[3]  R. Doggett,et al.  Pseudomonas aeruginosa : clinical manifestations of infection and current therapy , 1979 .

[4]  G. Pier,et al.  Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa , 1978, Infection and immunity.

[5]  B. Wretlind,et al.  Experimental infections with protease-deficient mutants of Pseudomonas aeruginosa in mice. , 1978, Journal of medical microbiology.

[6]  I. A. Holder,et al.  Role of Exotoxin and Protease as Possible Virulence Factors in Experimental Infections with Pseudomonas aeruginosa , 1978, Infection and immunity.

[7]  M. Pollack,et al.  Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections , 1977, Infection and immunity.

[8]  L. Hazlett,et al.  Pseudomonas eye infections in cyclophosphamide-treated mice. , 1977, Investigative ophthalmology & visual science.

[9]  B. Andersen,et al.  Passive immunity against pseudomonas sepsis during granulocytopenia , 1976, Infection and immunity.

[10]  B. Andersen,et al.  Evaluation of type-specific and non-type-specific pseudomonas vaccine for treatment of pseudomonas sepsis during granulocytopenia , 1976, Infection and immunity.

[11]  J. Grogan Pseudomonas aeruginosa infection in mice after treatment with cyclophosphamide. , 1975, Archives of surgery.

[12]  J. Pennington,et al.  Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis. , 1975, The American journal of medicine.

[13]  D. Armstrong,et al.  Bacteremia due to Pseudomonas aeruginosa complicating neoplastic disease: a progress report. , 1974, The Journal of infectious diseases.

[14]  P. Wiernik,et al.  Significance of Pseudomonas aeruginosa in the patient with leukemia or lymphoma. , 1974, The Journal of infectious diseases.

[15]  B. Andersen,et al.  Pseudomonas Septicemia in Neutropenic Dogs I. Treatment with Granulocyte Transfusions , 1974, Transfusion.

[16]  D. Armstrong,et al.  Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia , 1973, Cancer.

[17]  L. Young,et al.  Pseudomonas aeruginosa vaccine in cancer patients. , 1973, Annals of internal medicine.

[18]  L. Young,et al.  Pseudomonas aeruginosa infections. , 2008, CRC critical reviews in clinical laboratory sciences.

[19]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .